Akari Therapeutics, Plc
AKTX
$3.06
-$2.09-40.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.30M | -6.40M | -1.90M | -3.71M | -3.77M |
| Total Depreciation and Amortization | -- | -- | -- | -- | 1.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.24M | 4.85M | -945.00K | 988.00K | 104.00K |
| Change in Net Operating Assets | 20.00K | -575.00K | -416.00K | 567.00K | 1.54M |
| Cash from Operations | -3.04M | -2.12M | -3.26M | -2.15M | -2.12M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 382.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 382.00K |
| Total Debt Issued | 0.00 | 2.10M | -- | -- | 0.00 |
| Total Debt Repaid | -122.00K | -202.00K | -214.00K | -514.00K | -973.00K |
| Issuance of Common Stock | 4.85M | 0.00 | 3.27M | 2.65M | 3.13M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.04M | 0.00 | 330.00K | -- | -- |
| Cash from Financing | 5.76M | 1.90M | 3.38M | 2.13M | 2.15M |
| Foreign Exchange rate Adjustments | 0.00 | -3.00K | 4.00K | -- | 1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.72M | -227.00K | 129.00K | -17.00K | 413.00K |